Patterns of Non-injection Drug Use Associated with Injection Cessation among Street-Involved Youth in Vancouver, Canada

Stephanie Lake · Thomas Kerr · Ekaterina Nosova ·
M-J Milloy · Evan Wood · Kora DeBeck

Published online: 8 February 2018
© The New York Academy of Medicine 2018

Abstract Although abstinence from drug use is often a key goal of youth substance use treatment, transitioning to less harmful routes and types of drug use is desirable from both a clinical and public health perspective. Despite this, little is known about the trajectories of youth who inject drugs including changes in patterns of non-injection drug use. The At-Risk Youth Study (ARYS) is a longitudinal cohort of street-involved youth who use drugs in Vancouver, Canada. We used linear growth curve modeling to compare changes in non-injection drug use among participants who ceased injecting drugs for at least one 6-month period between September 2005 and May 2015 to matched controls who continued injecting over the same period. Of 387 eligible

participants, 173 (44.7%) reported ceasing drug injection at least once. Non-injection drug use occurred during 160 (79.6%) periods of injection cessation. In adjusted linear growth curve analyses, the only non-injection drug use pattern observed to decrease significantly more than controls following injection cessation was daily crack/cocaine use ($p = 0.024$). With the exception of frequent crack/cocaine use, transitions out of injection drug use did not appear to coincide with increased reductions in patterns of non-injection drug use. Our findings indicate that most (80%) of the observed injection cessation events occurred in the context of ongoing substance use. Given that transitioning out of drug injection represents a significant reduction in risk and harm, efforts supporting vulnerable youth to move away from injecting may benefit from approaches that allow for ongoing non-injection drug use.

S. Lake · T. Kerr · E. Nosova · M.-J. Milloy · E. Wood ·
K. DeBeck
BC Centre on Substance Use, BC Centre for Excellence in HIV/
AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver,
BC V6Z 1Y6, Canada

S. Lake
School of Population and Public Health, University of British
Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada

T. Kerr · M.-J. Milloy · E. Wood
Department of Medicine, University of British Columbia, St.
Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z
1Y6, Canada

K. DeBeck (✉)
School of Public Policy, Simon Fraser University, Suite 3271 –
515 West Hastings Street, Vancouver, BC V6B 5K3, Canada
e-mail: uhri-kd@cfeenet.ubc.ca

Keywords Injection drug use · Injection cessation ·
Crack · Cocaine · Youth

Introduction

Reducing the burden of disease attributable to substance use among young people is a growing public health priority globally [1]. Among street-involved youth (i.e., young people who live and/or work on the street) [2, 3], injection drug use is a central public health concern, as it increases susceptibility to a range of severe drug-related morbidity and mortality including

HIV [4, 5] and hepatitis C infection [6, 7], bacterial infections (e.g., endocarditis) [8], and overdose [9, 10]. In settings across Canada, almost half of street-involved youth report a history of injection drug use [11, 12], and the majority of youth who initiate injecting drugs will progress to regular injection use within 1 month of their first injection [13]. Street-involved youth experience a mortality rate approximately 11 times higher than that of the age- and sex-matched general population [2, 3, 14] due to overdose, suicide, trauma/accidents, and medical conditions related to injection drug use [15]. Not surprisingly, injection drug use is a major predictor of mortality among them [2].

It has long been recognized that injecting careers are dynamic and complex processes, often involving recurring cessation and relapse [16], yet much of the research into injection trajectories among at-risk youth has focused on risk factors for injection initiation [17–20], while transitions out of injection drug use have not been as well characterized. Although many young individuals struggling with substance use disorders have benefitted from abstinence-based treatment models, it is also becoming increasingly clear, from high drop out and relapse rates [21–24], that they are far from universally beneficial and may even set the stage for severe drug-related harms. For example, the many individuals who relapse after discharge from abstinence-oriented treatment programs are highly susceptible to fatal overdose as a result of reduced drug tolerance [25–28]. In many settings, there is a significant portion of youth who do not access substance use treatment for various reasons including choosing to “handle their drug problem on their own” [29]. From a public health perspective, for those unable or unwilling to cease drug use completely (engaged in treatment or not), reducing use, transitioning from injection drug use to lower-risk methods of drug administration (e.g., smoking, intranasal) and/or comparatively less harmful drugs (e.g., cannabis) is considered favorable to continued injection drug use [30, 31]. This consideration is increasingly being adopted among substance use care experts as a valid option on the substance use care spectrum that can contribute to improved health on its own [32] or as part of a long-term bridge to abstinence [33, 34]. Ongoing non-injection drug use has been previously documented among youth throughout periods of injection cessation; for example, in a study of young people who inject drugs in Montreal, Canada, approximately one third of those who ceased injecting drugs did not abstain from

heroin and cocaine use during cessation [35]. However, very little is known about how patterns of non-injection drug use may change during transitions out of injection drug use. For example, the extent to which injection cessation is accompanied by transitions to complete abstinence from other forms of drug use, reductions in other modes of use, or even increases in other modes of use (i.e., substitution), has received little consideration in the context of public health approaches to harm reduction and drug treatment for youth.

Therefore, we conducted the present study among youth and young adults who inject drugs in Vancouver, Canada to: (1) examine how non-injection drug use changes from periods of active injection to periods of cessation of injection and (2) determine how these changes may differ from youth and young adults who continue to engage in active injection drug use.

Methods

Study Sample

Data for this study was derived from the At-Risk Youth Study, an ongoing prospective cohort of vulnerable street-involved youth and young adults who use illicit drugs. This study has been described in detail previously [36]. In brief, participants are recruited through self-referral, snowball sampling, and extensive street outreach in various areas of downtown Vancouver including the Downtown Eastside (DTES), a lower-income neighborhood known for its open illicit drug use scene, and the Downtown South, an area often frequented by transient, homeless, or vulnerable youth. To be eligible for ARYS, participants must provide written informed consent, be under 26 years of age, report using an illicit drug other than (or in addition to) cannabis in the month prior to enrolment, and self-identify as “street involved,” defined as being recently homeless or having used services designated for street-involved youth in the preceding 6 months [2, 37].

At baseline and bi-annually, participants complete an interviewer-administered questionnaire eliciting information on time-updated sociodemographic, behavioral, and health-related exposures. Each participant also undergoes a consultation with a study nurse and is referred to appropriate health care services if needed. All participants receive a \$30 (CAD) honorarium upon completion of each study visit. The University of British

Columbia/Providence Health Care Research Ethics Board provided ethical approval for this study.

Measures

As we were interested in examining cessation of injection drug use, we restricted the study sample to youth who reported injection drug use at their baseline interview or at any point during the study period. Any participant who initiated injection drug use over the study period was included at the first follow-up where injection drug use was reported. Further, to assess for injection cessation, only participants who completed at least one subsequent study visit after a report of active injection drug use were considered for the analysis.

To examine patterns of non-injection drug use from periods of active injection to periods of injection cessation, we considered the following self-reported measures of non-injection drug use: crack/cocaine use, crystal methamphetamine use, heroin use, and cannabis use. We examined two dichotomized variables for each non-injection drug use measure: any use in the previous 6 months (at least once vs. none) and daily use in the previous 6 months (at least once/day vs. none). We defined injection cessation based on responses to the question: "In the last six months, when you were using, which of the following drugs did you inject, and how often?" Participants who reported not having injected any drugs following at least one previous report of active injection drug use were considered cases. Participants who did not cease injecting drugs over the study period were considered controls. For each cessation case, the injection cessation period was defined as the 6-month period referenced in the study visit where no injection drug use was reported. The active injection period was defined as the 6-month period referenced in the study visit preceding the injection cessation event. Cases could experience more than one cessation event.

We also considered potential demographic, social, and drug-related exposures that could potentially differ between cases and controls including: age; years of injection experience (per additional year); gender (female vs. male); ethnicity (Caucasian vs. other); regular employment (yes vs. no); homelessness, defined as having no fixed address, sleeping on the street, or staying in a shelter (yes vs. no); DTES residency, defined as residing or, for homeless or marginally housed youth, spending the majority of time in the DTES (yes vs. no); daily injection drug use (yes vs. no); crystal methamphetamine injection

(yes vs. no); heroin injection (yes vs. no); crack/cocaine injection; high-risk alcohol use (defined as exceeding the National Institutes on Alcohol Abuse and Alcoholism's definition of drinking at low-risk for developing alcohol use disorder: > 14 drinks per week or > 4 drinks per day for men, and > 7 drinks per week or > 3 drinks per day for women [38]; yes vs. no); methadone maintenance treatment (yes vs. no); non-methadone-based addiction treatment including detoxification services, outpatient treatment, and counseling services (yes vs. no); incarceration, defined as being in detention, prison, or jail (yes vs. no); sex work, defined as exchanging sex for money, drugs, or other material possessions (yes vs. no); and drug dealing (yes vs. no). All measures were self-reported, and, with the exception of gender and ethnicity, correspond to exposures in the previous 6 months.

Analysis

Baseline Comparisons

First, we characterized the study sample at baseline using chi-square tests (categorical variables) and Mann-Whitney *U* tests (continuous variables) to compare baseline exposures according to whether or not the participant ceased injecting over the study period (i.e., cases vs. controls).

Within-Group Changes from Injection to Injection Cessation

As cases could potentially experience more than one cessation event (e.g., cease, relapse, cease), we examined the data at the event level and conducted a sensitivity analysis using the first event of injection cessation. Each cessation event consisted of a pair of observations from an active injection period (i.e., the 6-month period referenced in the study visit preceding the report of cessation) and a cessation period (i.e., reporting cessation in the previous 6-month period). We used McNemar's test to compare within-group changes in non-injection drug use from the active injection period to injection cessation period.

Within-Group Changes among Matched Controls

In order to account for potential changes in drug use patterns in the cohort over time, we also examined changes in non-injection drug use among individuals

who did not cease injection (i.e., controls). Similar to case events described above, we created control “events,” consisting of a pair of observations from two consecutive follow-up periods in which the participant reported injecting drugs. These control events were matched to case events via the 6-month follow-up periods corresponding to active injection and injection cessation, respectively, in case events. For example, a participant who reported injecting drugs in the 6-month follow-up periods corresponding to December 2008–May 2009 and June 2009–November 2009 would be an eligible control event match for a case participant who reported injecting drugs during the 6-month follow-up period corresponding to December 2008–May 2009, and ceased injection drug use for the 6-month follow-up period corresponding to May 2009–November 2009. For each case event, we randomly selected two control events from the pool of time-matched eligible controls, without replacement (i.e., after a control event was selected from the pool of eligible matched controls, it was ineligible to be selected as a control for another time-matched event case). McNemar’s test was used to examine within-group changes in non-injection drug use patterns from the first 6-month injection period to the second 6-month injection period. To maximize the stability of our control estimates, we used a bootstrapping method in which we repeated control selection and McNemar’s test 50 times for each case (removing any duplicate control follow-up pairs for each case follow-up pair), and reported results as a summary (i.e., average) of 50 runs.

Between-Group Differences in Case and Control Changes

To determine whether the changes in non-injection drug use patterns from active injection to injection cessation differed significantly than matched controls, we built linear growth curve models [39], adjusting for all variables that differed between case and control events in the active injection period at $p < 0.10$. These differences were estimated through generalized estimating equations to account for multiple observations among individuals who ceased injecting more than once, and for repeated measures among controls. In the multivariate linear growth curve models, the slope represents the change in non-injection drug use pattern by group (i.e., case or control) over time (active injection vs. cessation period), and the p value corresponds to the significance

of the interaction term. Variations of this method have been previously used in studies of PWUD to compare between-group differences in within-group changes over time [40–42]. However, we have built on these previous approaches by employing a bootstrapping method to summarize results (i.e., slope estimates and 95% confidence intervals) from 50 runs (see description above). All tests of significance were two-sided with significance fixed at $\alpha = 0.05$, and performed using RStudio Version 0.99.892 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Between September 2005 and May 2015, of 1209 ARYS participants, 545 (45.1%) reported injecting drugs at baseline or during at least once during study follow-up. Of those, 387 (71.0%) participants were seen more than once and were included in this analysis. Compared to the analytic sample, participants excluded for insufficient follow-up were more likely to inject crack/cocaine at baseline (42.4 vs. 30.2%, $p = 0.005$), but did not differ from the analytic sample in terms of demographic characteristics or other types of drugs injected. In total, the study sample contributed 1976 analytic observations to the analysis. Table 1 summarizes the baseline characteristics of the sample, stratified by injection cessation over the study period. The most commonly injected drug at baseline was heroin ($n = 261$; 67.4%), closely followed by crystal methamphetamine ($n = 235$; 60.7%), then crack/cocaine ($n = 117$; 30.2%). In addition, 325 (84.0%) participants reported cannabis use at baseline. Participants who went on to cease injection drug use for at least one 6-month period were less likely at baseline to report daily drug injection, any crystal methamphetamine injection, and any heroin injection, and were more likely to report daily use of crack or cocaine (all $p < 0.05$). At baseline, those who ceased injecting at least once were also less likely to be on methadone maintenance treatment or any non-methadone form of addiction treatment (both $p < 0.05$).

Overall, 173 (44.7%) participants reported ceasing injection drug use for at least one 6-month follow-up period, yielding a total of 201 cessation events. The use of non-injection drugs occurred during 79.6% ($n = 160$) of injection cessation periods, and occurred daily during 53.7% ($n = 108$) injection cessation periods. Table 2 summarizes non-injection drug use patterns among

Table 1 Descriptive characteristics of the study sample at baseline, stratified by whether or not participants ceased injection drug use for at least one 6-month period

Characteristic	Total, <i>n</i> = 387 <i>n</i> (%)	Ceased injecting at least once over the study period		<i>p</i> value
		Yes, <i>n</i> = 173 <i>n</i> (%)	No, <i>n</i> = 214 <i>n</i> (%)	
Demographic				
Age ^a				
Median (IQR)	22.4 (20.5–24.1)	22.4 (20.4–24.1)	22.4 (20.6–24.1)	0.818
Gender				
Female	138 (35.7)	70 (40.5)	68 (31.8)	0.076
Male	249 (64.3)	103 (59.5)	146 (68.2)	
Ethnicity				
Caucasian	276 (71.3)	126 (72.8)	150 (70.1)	0.270
Non-Caucasian	110 (28.4)	47 (27.2)	63 (29.4)	
Education				
≥ Secondary	122 (31.5)	59 (34.1)	63 (29.4)	0.337
< Secondary	262 (67.7)	113 (65.3)	149 (69.6)	
Employment ^b				
Yes	158 (40.8)	63 (36.4)	95 (44.4)	0.112
No	229 (59.2)	110 (63.6)	119 (55.6)	
Homeless ^b				
Yes	284 (73.4)	122 (70.5)	162 (75.7)	0.256
No	101 (26.1)	50 (28.9)	51 (23.8)	
DTES residency ^b				
Yes	149 (38.5)	66 (38.2)	83 (38.8)	0.898
No	238 (61.5)	107 (61.9)	131 (61.7)	
Injection drug use ^b				
Daily injection drug use				
Yes	121 (31.3)	39 (22.5)	82 (38.3)	0.001
No	266 (68.7)	134 (77.5)	132 (61.2)	
Crystal meth injection				
Yes	235 (60.7)	93 (53.8)	142 (66.4)	0.014
No	151 (39.0)	79 (45.7)	72 (33.6)	
Heroin injection				
Yes	261 (67.4)	96 (55.5)	165 (77.1)	< 0.001
No	126 (32.6)	77 (44.5)	49 (22.9)	
Crack/cocaine injection				
Yes	117 (30.2)	47 (27.2)	70 (32.7)	0.253
No	269 (69.5)	125 (72.3)	144 (67.3)	
Non-injection drug use ^b				
Crystal meth				
Yes	217 (56.1)	94 (54.3)	123 (57.5)	0.536
No	170 (43.9)	79 (45.7)	91 (42.5)	
Daily crystal meth				
Yes	54 (14.0)	26 (15.0)	28 (13.1)	0.583
No	333 (86)	147 (85.0)	186 (86.9)	

Table 1 (continued)

Characteristic	Total, <i>n</i> = 387 <i>n</i> (%)	Ceased injecting at least once over the study period		<i>p</i> value
		Yes, <i>n</i> = 173 <i>n</i> (%)	No, <i>n</i> = 214 <i>n</i> (%)	
Heroin				
Yes	134 (34.6)	65 (37.6)	69 (32.2)	0.273
No	253 (65.4)	108 (62.4)	145 (67.8)	
Daily heroin				
Yes	21 (5.4)	8 (4.6)	13 (6.1)	0.531
No	366 (94.6)	165 (95.4)	201 (93.9)	
Crack/cocaine				
Yes	273 (70.5)	129 (74.6)	144 (67.3)	0.118
No	114 (29.5)	44 (25.4)	70 (32.7)	
Daily crack/cocaine				
Yes	66 (17.1)	38 (22.0)	28 (13.1)	0.021
No	321 (82.9)	135 (78.0)	186 (86.9)	
Cannabis				
Yes	325 (84.0)	144 (83.2)	181 (84.6)	0.720
No	62 (16.0)	29 (16.8)	33 (15.4)	
Daily Cannabis				
Yes	145 (37.5)	65 (37.6)	80 (37.4)	0.970
No	242 (62.5)	108 (62.4)	134 (62.6)	
High-risk alcohol				
Yes	94 (24.5)	44 (25.4)	51 (23.8)	0.716
No	293 (75.7)	129 (74.6)	163 (76.2)	
Social ^b				
Methadone treatment				
Yes	55 (14.2)	17 (9.8)	38 (17.8)	0.029
No	330 (85.3)	154 (89.0)	176 (82.2)	
Other addiction treatment				
Yes	157 (40.6)	60 (34.7)	97 (45.3)	0.042
No	228 (58.9)	111 (64.2)	117 (54.7)	
Incarceration				
Yes	83 (21.5)	36 (20.8)	47 (22.0)	0.806
No	303 (78.3)	136 (78.6)	167 (78.0)	
Sex work				
Yes	59 (16.3)	27 (15.6)	32 (15.0)	0.859
No	328 (84.8)	146 (84.4)	182 (85.1)	
Drug dealing				
Yes	197 (50.9)	88 (50.9)	109 (50.9)	0.989
No	190 (49.1)	85 (49.1)	105 (49.1)	

Some cells may not add up to 100% as participants can refuse to answer questions

^a *p* value generated with Wilcoxon rank-sum test

^b Refers to exposures in the previous 6 months

cases and controls, for active injection and cessation periods. As shown, significant decreases in non-injection crack/cocaine use (any and daily), crystal methamphetamine use (any), heroin use (any), and cannabis use (any) were observed among cases following shifts from active injection to injection cessation periods (all $p < 0.001$). Over the same study follow-up period, significant decreases were also observed in crack/cocaine use (any) and cannabis use (any) among matched controls (youth who continued injecting over the same period) summarized over 50 runs. Interestingly, the proportion of cases reporting daily non-injection heroin use did not change during transitions away from injection ($p = 1.00$). The only increase in non-injection drug use observed among either cases or controls was a slight increase (37.3 to 41.3%) in daily cannabis use among cases following shifts to injection cessation, compared to a slight average decrease (34.1 to 31.9%) over the same study follow-up periods among controls. Neither of these within-group changes reached statistical significance.

When we compared changes in non-injection drug use from periods of injection to injection cessation among cases to corresponding follow-up periods among controls, controlling for group differences during the active injection (i.e., “pre-cessation”) period (Table 3), we found that the decrease in daily crack/cocaine use among cases was significantly more than the decrease among controls (average p value = 0.024). No other between-group changes in non-injection drug use were found to be statistically significant.

We also removed any secondary cessation events and examined the first (if not only) cessation event per case. In these analyses, we also observed decreases in daily crack cocaine (average $p = 0.026$), but not other non-injection drug use patterns, to be significantly greater for cases than controls (data not shown).

Discussion

In this study of street-involved youth who inject drugs, we observed that 6-month cessation of injection was common with 45% of participants reporting cessation at least once over a 10-year period (September 2005 and May 2015). This proportion is higher than an estimate of 29% over an 8-year period among young people who inject drugs (PWID) in San Francisco, USA, with the same median age [43], but substantially lower than a

70% estimate recorded among PWID (median age, 34) in Baltimore, USA, over a similar length of study period [44]. The proportion of individuals reporting non-injection drug use generally decreased following the shift from the active injection to injection cessation, yet the prevalence of non-injection drug use remained relatively high following injection cessation. Overall, non-injection of at least one drug following injection cessation occurred for over three-quarters of cessation events.

To our knowledge, this is the first study to examine changes in non-injection drug use that accompany transitions out of injection drug use among youth. Our study was novel in that it used matched controls to examine the extent to which observed changes would have likely occurred in the cohort in the absence of injection cessation. Interestingly, when changes in non-injection drug use trends among cases and controls were compared, only daily non-injection use of crack/cocaine was found to decrease significantly more than controls from periods of active injection to injection cessation. This finding is particularly promising considering prior research that has pointed to non-injection cocaine use as a significant predictor of relapse to injection drug use after injection cessation [44]. Overall, however, our findings demonstrate that although cessation of injection drug use occurs regularly, it is often in the context of continued use of non-injection drugs. Furthermore, continued engagement in lower-risk (i.e., non-injection) drug use during cessation of injection suggests an important harm reduction opportunity, suggesting that at-risk youth may benefit from models of substance use care that operate from or incorporate a harm reduction philosophy. Specifically, as abstinence-based models are still the norm in many youth addiction treatment services [24], these findings lend support to the notion that youth treatment models should consider a range of pathways to wellness including expanding strategies that can help youth transition to safer forms of drug use without requiring abstinence as the sole objective. This recommendation is consistent with prior research suggesting that abstinence from all substance use may not be common among many street-involved youth [45], and is made with careful consideration of the frequent shortcomings (e.g., dropout, relapse) [21–24] and risk of harm (e.g., overdose) [25–28] associated with abstinence-oriented treatment models.

In light of descriptive studies among other populations, including medical and non-medical cannabis

Table 2 Non-injection drug use reported for the period before and after injection cessation among cases ($n = 201$ events) and matched controls (average n over 50 runs = 231 events).

Non-injection drug use ^a	Drug use period		<i>p</i> value ^b
	Before injection cessation, <i>n</i> (%)	During injection cessation, <i>n</i> (%)	
Crack/cocaine			
Any			
Cases	126 (62.7)	77 (38.3)	<0.001
Controls ^c	130 (56.5)	96 (41.6)	<0.001
Daily			
Cases	41 (20.4)	13 (6.5)	< 0.001
Controls ^c	29 (12.7)	26 (11.3)	0.549
Crystal methamphetamine			
Any			
Cases	88 (43.8)	67 (33.3)	< 0.001
Controls ^c	107 (46.6)	87 (37.8)	0.087
Daily			
Cases	29 (14.4)	19 (9.5)	0.078
Controls ^c	23 (9.8)	22 (9.7)	0.632
Heroin			
Any			
Cases	60 (29.9)	26 (12.9)	< 0.001
Controls ^c	54 (23.3)	39 (16.7)	0.145
Daily			
Cases	14 (7.0)	14 (7.0)	1.000
Controls ^c	10 (4.3)	6 (2.7)	0.465
Cannabis			
Any			
Cases	159 (79.1)	129 (64.2)	< 0.001
Controls ^c	178 (76.7)	157 (68.0)	0.037
Daily			
Cases	75 (37.3)	83 (41.3)	0.291
Controls ^c	79 (34.4)	74 (31.9)	0.504

^aRefers to drug use patterns in the previous 6 months^bThe p value for controls is an average of 50 runs^c n represents the number of events corresponding to each non-injection drug use pattern in each set of matched controls, averaged over 50 runs and rounded to the nearest decimal; the % is calculated as n divided by the number of matched controls in a run, averaged over 50 runs

users in California that have demonstrated cannabis use as a substitute for illicit drugs [31, 46], we were interested in potential increases in cannabis use during injection cessation periods. In our study, which examined aggregate-level trends in cannabis use, we noted that daily cannabis use was the only non-injection drug use pattern to increase among cases in the follow-up period corresponding to injection cessation; however, these changes were not statistically different from controls.

Findings from our study should be interpreted in the context of certain limitations. Since it is not possible to generate a random sample of hard-to-reach populations such as street-involved youth, our findings cannot be generalized to all street-involved youth who inject drugs in Vancouver or in other settings. We also relied on self-reported measures of drug use and other sensitive personal information, which is subject to response bias including social desirability bias. However, we have

Table 3 Comparison of changes in non-injection drug use patterns before and after a period of injection cessation between cases ($n = 201$ events) and matched controls (average n over 50 runs = 231 events)

Non-injection drug use ^a	Slope (95% CI)	<i>p</i> value ^b
Crack/cocaine		
Any		
Cases	−0.18 (−0.35; −0.02)	0.488
Controls ^c	−0.14 (−0.15; −0.13)	
Daily		
Cases	−0.13 (−0.24; −0.01)	0.024
Controls ^c	−0.02 (−0.03; −0.01)	
Crystal methamphetamine		
Any		
Cases	0.01 (−0.16; 0.17)	0.218
Controls ^c	−0.08 (−0.09; −0.07)	
Daily		
Cases	−0.02 (−0.13; 0.10)	0.648
Controls ^c	0.00 (−0.01; 0.01)	
Heroin		
Any		
Cases	−0.10 (−0.24; 0.05)	0.560
Controls ^c	−0.06 (−0.07; −0.05)	
Daily		
Cases	0.02 (−0.05; 0.09)	0.212
Controls ^c	−0.02 (−0.02; −0.02)	
Cannabis		
Any		
Cases	−0.07 (−0.21; 0.07)	0.709
Controls ^c	−0.07 (−0.08; −0.06)	
Daily		
Cases	0.07 (−0.08; 0.21)	0.217
Controls ^c	−0.01 (−0.02; 0.00)	

All estimates are adjusted for variables that differed between “cases” and “controls” in the 6-month period preceding injection cessation: gender, education, DTES residency, high-risk alcohol use, crystal methamphetamine injection, and heroin injection

^a Refers to drug use patterns in the previous 6 months

^b The p value is calculated as an average of 50 runs

^c Slope estimates for controls represent an average of 50 runs

no reason to suspect that respondent accuracy on patterns of drug use would differ according to injection cessation status or cessation period. Recognizing that non-medical use of pharmaceutical opioids remains a prevalent trend among some populations of at-risk youth [47], and has been linked to injection initiation

[48], we had also intended to examine changes in non-injection use of pharmaceutical opioids during transitions to injection cessation. However, relatively low cell counts for daily and any non-injection pharmaceutical opioid use prevented us from including this data in the present analysis. Finally, we cannot overlook the possibility that youth who cease all illicit drug use may be less likely to return for subsequent study visits, potentially reducing the estimated proportion of cases who ceased non-injection drug use. Nevertheless, we did note that there were few differences at baseline between those who were retained in our study and those who were excluded for a lack of follow-up.

With the exception of daily use of crack/cocaine, decreases in non-injection drug use following shifts to injection cessation among our sample do not differ significantly from youth who continue to inject. While transitioning out of injection drug use occurred for almost half of our sample, these transitions were largely accompanied by continued use of drugs through lower-risk modes of administration. Given that these shifts represent significant reductions in risks for drug-related harm, our findings suggest that novel strategies promoting safer substance use and transitions away from injecting should be urgently evaluated. These programs may compliment traditional abstinence-based approaches that may not be suitable for all youth. Treatment and care models focused on at-risk youth should specifically consider broadening their objectives and expanding services to reach those not ready to abstain from all modes and types of drug use but who may be ready and willing to shift to less risky forms of substance use.

Acknowledgments We extend our gratitude to the participants of the At-Risk Youth Study for their contribution to the research. We would also like to thank past and present study staff including Cody Callon, Sabina Dobrer, Deborah Graham, Peter Vann, Steve Kain, and Tricia Collingham for their administrative support.

Funding This study was supported by the United States National Institutes of Health (U01DA038886). Stephanie Lake is supported through doctoral awards from the Canadian Institutes of Health Research (CIHR) and the Pierre Elliott Trudeau Foundation (2017). Dr. Kora DeBeck is supported by a Michael Smith Foundation for Health Research/St. Paul's Hospital Foundation-Providence Health Care Career Scholar Award and a CIHR New Investigator Award. Dr. Evan Wood receives support through a Tier 1 Canada Research Chair in Inner City Medicine. Dr. Kerr is supported by a foundation grant from the Canadian Institutes of Health Research (20R74326). Dr. Milloy is supported in part by the United States National Institutes on Health (R01-DA0251525),

a New Investigator award from CIHR and a Scholar Award from the Michael Smith Foundation for Health Research. His institution has received an unstructured gift to support his research from NG Biomed, Ltd., an applicant to the Canadian federal government for a license to produce medical cannabis. Funding sources had no role in the design of this study; collection, analysis, and interpretation of the data; writing of the report; or the decision to submit the paper for publication.

References

- Degenhardt L, Stockings E, Patton G, Hall WD, Lynskey M. The increasing global health priority of substance use in young people. *Lancet Psychiatry*. 2016;3(3):251–64. [https://doi.org/10.1016/S2215-0366\(15\)00508-8](https://doi.org/10.1016/S2215-0366(15)00508-8).
- Roy E, Haley N, Leclerc P, Sochanski B, Boudreau JF, Boivin JF. Mortality in a cohort of street youth in Montreal. *JAMA*. 2004;292(5):569–74. <https://doi.org/10.1001/jama.292.5.569>.
- Boivin JF, Roy E, Haley N, du Fort GG. The health of street youth: a Canadian perspective. *Can J Public Health*. 2005;96(6):432–7.
- Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxycodone in Indiana, 2014–2015. *N Engl J Med*. 2016;375(3):229–39. <https://doi.org/10.1056/NEJMoal515195>.
- Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. *AIDS*. 2003;17(6):887–93. <https://doi.org/10.1097/00002030-200304110-00014>.
- Suryaprasad AG, White JZ, Xu FJ, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. *Clin Infect Dis*. 2014;59(10):1411–9. <https://doi.org/10.1093/cid/ciu643>.
- Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D, et al. Incidence—a comparison between injection and noninjection drug users in New York City. *J Urban Health*. 2004;81(1):20–4. <https://doi.org/10.1093/jurban/jth084>.
- Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. *Clin Infect Dis*. 2007;45(9):1200–3. <https://doi.org/10.1086/522176>.
- Ochoa KC, Hahn JA, Seal KH, Moss AR. Overdosing among young injection drug users in San Francisco. *Addict Behav*. 2001;26(3):453–60. [https://doi.org/10.1016/S0306-4603\(00\)00115-5](https://doi.org/10.1016/S0306-4603(00)00115-5).
- Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. *Drug Alcohol Depend*. 2007;87(1):39–45. <https://doi.org/10.1016/j.drugalcdep.2006.07.009>.
- Roy E, Boudreau JF, Leclerc P, Boivin JF, Godin G. Trends in injection drug use behaviors over 10 years among street youth. *Drug Alcohol Depend*. 2007;89(2–3):170–5. <https://doi.org/10.1016/j.drugalcdep.2006.12.025>.
- Kerr T, Marshall BD, Miller C, et al. Injection drug use among street-involved youth in a Canadian setting. *BMC Public Health*. 2009;9(1):171. <https://doi.org/10.1186/1471-2458-9-171>.
- Debeck K, Kerr T, Marshall BD, Simo A, Montaner J, Wood E. Risk factors for progression to regular injection drug use among street-involved youth in a Canadian setting. *Drug Alcohol Depend*. 2013;133(2):468–72. <https://doi.org/10.1016/j.drugalcdep.2013.07.008>.
- Auerswald CL, Lin JS, Parriott A. Six-year mortality in a street-recruited cohort of homeless youth in San Francisco, California. *PeerJ*. 2016;4:e1909. <https://doi.org/10.7717/peerj.1909>.
- Evans JL, Tsui JJ, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. *Am J Epidemiol*. 2012;175(4):302–8. <https://doi.org/10.1093/aje/kwr318>.
- Roy E, Lemire N, Haley N, Boivin JF, Frappier JY, Claessens C. Injection drug use among street youth: a dynamic process. *Can J Public Health*. 1998;89(4):239–40.
- Miller CL, Strathdee SA, Kerr T, Li K, Wood E. Factors associated with early adolescent initiation into injection drug use: implications for intervention programs. *J Adolesc Health*. 2006;38(4):462–4. <https://doi.org/10.1016/j.jadohealth.2005.03.004>.
- Harocopos A, Goldsamt LA, Kobrak P, Jost JJ, Clatts MC. New injectors and the social context of injection initiation. *Int J Drug Policy*. 2009;20(4):317–23. <https://doi.org/10.1016/j.drugpo.2008.06.003>.
- Roy E, Boivin JF, Leclerc P. Initiation to drug injection among street youth: a gender-based analysis. *Drug Alcohol Depend*. 2011;114(1):49–54. <https://doi.org/10.1016/j.drugalcdep.2010.09.003>.
- Sherman SG, Fuller CM, Shah N, Ompad DV, Vlahov D, Strathdee SA. Correlates of initiation of injection drug use among young drug users in Baltimore, Maryland: the need for early intervention. *J Psychoactive Drugs*. 2005;37(4):437–43. <https://doi.org/10.1080/02791072.2005.10399817>.
- Matson SC, Hobson G, Abdel-Rasoul M, Bonny AEA. Retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. *J Addict Med*. 2014;8(3):176–82. <https://doi.org/10.1097/ADM.0000000000000035>.
- Stein BD, Kogan JN, Sorbero M. Substance abuse detoxification and residential treatment among Medicaid-enrolled adults: rates and duration of subsequent treatment. *Drug Alcohol Depend*. 2009;104(1–2):100–6. <https://doi.org/10.1016/j.drugalcdep.2009.04.008>.
- Williams RJ, Chang SY. A comprehensive and comparative review of adolescent substance abuse treatment outcome. *Clin Psychol Sci Pract*. 2000;7(2):138–66. <https://doi.org/10.1093/clipsy.7.2.138>.
- Winters KC, Botzet AM, Fahnhorst T. Advances in adolescent substance abuse treatment. *Curr Psychiatry Rep*. 2011;13(5):416–21. <https://doi.org/10.1007/s11920-011-0214-2>.
- Merrall EL, Bird SM, Hutchinson SJ. A record-linkage study of drug-related death and suicide after hospital

- discharge among drug-treatment clients in Scotland, 1996–2006. *Addiction*. 2013;108(2):377–84. <https://doi.org/10.1111/j.1360-0443.2012.04066.x>.
26. Ravndal E, Amundsen EJ. Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study. *Drug Alcohol Depend*. 2010;108(1–2):65–9. <https://doi.org/10.1016/j.drugalcdep.2009.11.008>.
 27. Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. *BMJ*. 2003;326(7396):959–60. <https://doi.org/10.1136/bmj.326.7396.959>.
 28. Walley AY, Cheng DM, Quinn EK, Blokhina E, Gnatenko N, Chaisson CE, et al. Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/AIDS who inject drugs. *Int J Drug Policy*. 2017;39:114–20. <https://doi.org/10.1016/j.drugpo.2016.10.022>.
 29. Hadland SE, Kerr T, Li K, Montaner JS, Wood E. Access to drug and alcohol treatment among a cohort of street-involved youth. *Drug Alcohol Depend*. 2009;101(1–2):1–7. <https://doi.org/10.1016/j.drugalcdep.2008.10.012>.
 30. Lucas P, Reiman A, Earleywine M, et al. Cannabis as a substitute for alcohol and other drugs: a dispensary-based survey of substitution effect in Canadian medical cannabis patients. *Addiction Res Theory*. 2013;21(5):435–42.
 31. Reiman A. Cannabis as a substitute for alcohol and other drugs. *Harm Reduct J*. 2009;6(1):35. <https://doi.org/10.1186/1477-7517-6-35>.
 32. Draanen J, Comeau S, Henderson T, Quastel A, Griller R, Stergiopoulos V. Reducing service and substance use among frequent service users: a brief report from the Toronto Community Addictions Team. *Subst Use Misuse*. 2013;48(7):532–8. <https://doi.org/10.3109/10826084.2013.787096>.
 33. Davis AK, Lauritsen KJ. Acceptability of non-abstinence goals among students enrolled in addiction studies programs across the United States. *Subst Abuse*. 2016;37(1):204–8. <https://doi.org/10.1080/08897077.2015.1015702>.
 34. Rosenberg H, Davis AK. Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians. *J Subst Abuse Treat*. 2014;46(2):214–8. <https://doi.org/10.1016/j.jsat.2013.07.005>.
 35. Steensma C, Boivin JF, Blais L, Roy E. Cessation of injecting drug use among street-based youth. *J Urban Health*. 2005;82(4):622–37. <https://doi.org/10.1093/jurban/jti121>.
 36. Wood E, Stoltz J-A, Montaner JSG, Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. *Harm Reduct J*. 2006;3(1):18. <https://doi.org/10.1186/1477-7517-3-18>.
 37. Werb D, Kerr T, Li K, Montaner J, Wood E. Risks surrounding drug trade involvement among street-involved youth. *Am J Drug Alcohol Abuse*. 2008;34(6):810–20. <https://doi.org/10.1080/00952990802491589>.
 38. National Institute on Alcohol Abuse and Alcoholism. Drinking Levels Defined. 2017; Available at: <http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking>. Accessed September 1, 2015.
 39. Burant CJ. Latent growth curve models: tracking changes over time. *Int J Aging Hum Dev*. 2016;82(4):336–50. <https://doi.org/10.1177/0091415016641692>.
 40. Vlahov D, Safaie M, Lai S, Strathdee SA, Johnson L, Sterling T, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. *AIDS*. 2001;15(17):2311–6. <https://doi.org/10.1097/00002030-200111230-00013>.
 41. DeBeck K, Kerr T, Li K, Milloy MJ, Montaner J, Wood E. Incarceration and drug use patterns among a cohort of injection drug users. *Addiction*. 2009;104(1):69–76. <https://doi.org/10.1111/j.1360-0443.2008.02387.x>.
 42. Lake S, Milloy MJ, Dong H, Hayashi K, Wood E, Kerr T, et al. Initiation into prescription opioid injection and associated trends in heroin use among people who use illicit drugs. *Drug Alcohol Depend*. 2016;169:73–9. <https://doi.org/10.1016/j.drugalcdep.2016.10.017>.
 43. Evans JL, Hahn JA, Lum PJ, Stein ES, Page K. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). *Drug Alcohol Depend*. 2009;101(3):152–7. <https://doi.org/10.1016/j.drugalcdep.2008.12.007>.
 44. Shah NG, Galai N, Celentano DD, Vlahov D, Strathdee SA. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988–2000. *Drug Alcohol Depend*. 2006;83(2):147–56. <https://doi.org/10.1016/j.drugalcdep.2005.11.007>.
 45. Gaetz S, O'Grady W, Buccieri K, Karabanow J, Marsolais A. *Youth Homelessness in Canada: implications for Policy and Practice*. Toronto, CA: Canadian Homeless Research Network. 2013;
 46. Lau N, Sales P, Averill S, Murphy F, Sato SO, Murphy SA. Safer alternative: Cannabis substitution as harm reduction. *Drug Alcohol Rev*. 2015;34(6):654–9. <https://doi.org/10.1111/dar.12275>.
 47. Novak SP, Bluthenthal R, Wenger L, Chu D, Kral AH. Initiation of heroin and prescription opioid pain relievers by birth cohort. *Am J Public Health*. 2015;106(2):298–300. <https://doi.org/10.2105/AJPH.2015.302972>.
 48. Al-Tayyib AA, Koester S, Riggs P. Prescription opioids prior to injection drug use: comparisons and public health implications. *Addict Behav*. 2017;65:224–8. <https://doi.org/10.1016/j.addbeh.2016.08.016>.